Gemcitabine, a first-line chemotherapeutic agent for lung cancer [5, 6], has shown limitations in its absorption when tumor cells express low levels of nucleoside transporters such as human equilibrative nucleoside transporter 1 (hENT1), reducing its efficacy [7–10]. Here, SLC29A1 is linked to neoplasm.